SARM1 and multiple sclerosis: The clinical course of EAE, however, did not differ substantially between Sarm1 knockout and wild type littermates, suggesting that targeting SARM1 may not produce reliable clinical benefits in EAE or other immune-mediated CNS inflammatory disorders such as multiple sclerosis.